Drugs / Myelostim
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03055247 | Nov 2015 → Jul 2023 overdue | granulomatous disease, chronic, X-linked | IRCCS San Raffaele | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Myelostim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03055247 ↗ |
| Known as | G-CSF | “Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.” NCT03055247 ↗ |
| Route | Subcutaneous | “administered subcutaneously from day 19 to the day of the last LP.” NCT03055247 ↗ |